Clinical trial · Observational
Bone Loss in Men on Androgen Blockade as Adjuvant Therapy for Prostate Cancer
NCT00199537CI-TRIAL-00001624completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with advanced prostate cancer undergoing adjuvant treatment with androgen blockade will be followed over a 1 year interval to assess the effects of this treatment on bone metabolism. It is expected that men undergoing androgen blockade will experience accelerated bone loss.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Loss | — | UNRESOLVED | — |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * Men * Age of 40 years or greater * Diagnosis of advanced prostate cancer (ie: prostate-specific antigen \[PSA\] less than 25 ug/L and undergoing continued treatment with leuteinizing hormone-releasing hormone \[LHRH\] therapy) * Willing and able to consent Exclusion Criteria: * Metastatic disease to bone * Medications affecting bone turnover (bisphosphonate, steroids, anticonvulsant) * Renal failure (serum creatinine \> 200 umol/L) * Co-morbidity factors affecting bone density (ie: Paget's, rheumatoid arthritis) * Factors affecting ability to perform the bone density tests using femoral head measurements (ie: bilateral hip arthroplasty) * Cancer other than skin, except when, in the investigators' opinion, it is determined to be appropriate and not adversely affect the outcome of the trial * Gastrointestinal (GI) pathology (eg. malabsorption syndrome) * Parathyroid disease
References
Publications (0)
Data not yet available
No reference posted for this study.